Tanshinone IIA Inhibits Triple-Negative Breast Cancer Cells MDA-MB-231 via G Protein-Coupled Estrogen Receptor- (GPER-) Dependent Signaling Pathway.
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
08
2022
revised:
04
01
2023
accepted:
09
01
2023
entrez:
6
2
2023
pubmed:
7
2
2023
medline:
8
2
2023
Statut:
epublish
Résumé
Due to the lack of classic estrogen receptors, there has been a shortage of targeted therapy for triple-negative breast cancer (TNBC), resulting in a poor prognosis. However, the newly discovered G protein-coupled estrogen receptor (GPER) has been found to be expressed in TNBC cells.
Identifiants
pubmed: 36741908
doi: 10.1155/2023/8371623
pmc: PMC9897920
doi:
Substances chimiques
Receptors, Estrogen
0
tanshinone
03UUH3J385
Receptors, G-Protein-Coupled
0
GTP-Binding Proteins
EC 3.6.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8371623Informations de copyright
Copyright © 2023 Yueshuang He et al.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Nucleic Acids Res. 2016 Jan 4;44(D1):D1202-13
pubmed: 26400175
Int J Mol Sci. 2021 Apr 11;22(8):
pubmed: 33920463
Clin Cancer Res. 2018 Jul 1;24(13):2999-3004
pubmed: 29437768
Database (Oxford). 2010 Aug 05;2010:baq020
pubmed: 20689021
Int J Mol Sci. 2019 Jan 14;20(2):
pubmed: 30646517
Nat Chem Biol. 2008 Nov;4(11):682-90
pubmed: 18936753
J Clin Invest. 2015 May;125(5):2123-35
pubmed: 25893606
Nucleic Acids Res. 2021 Jan 8;49(D1):D605-D612
pubmed: 33237311
Cells. 2020 Oct 26;9(11):
pubmed: 33114740
Mol Cell Endocrinol. 2009 Sep 24;308(1-2):32-8
pubmed: 19464786
Cancer Med. 2019 May;8(5):1958-1975
pubmed: 30945475
Nat Rev Drug Discov. 2011 Jan;10(1):47-60
pubmed: 21193867
Ital J Anat Embryol. 2014;119(1):38-43
pubmed: 25345074
Chin Med. 2019 Nov 6;14:48
pubmed: 31719837
Breast Cancer Res. 2009;11(5):R77
pubmed: 19874578
Med Sci Monit. 2021 May 12;27:e929333
pubmed: 33979320
Nucleic Acids Res. 2014 Jan;42(Database issue):D1091-7
pubmed: 24203711
Breast Cancer Res Treat. 2014 Jul;146(2):273-85
pubmed: 24928526
J Biochem Mol Toxicol. 2021 Jan;35(1):e22620
pubmed: 32886829
Breast Cancer Res. 2020 Jun 9;22(1):61
pubmed: 32517735
Nucleic Acids Res. 2017 Jan 4;45(D1):D158-D169
pubmed: 27899622
Evid Based Complement Alternat Med. 2021 May 15;2021:9971403
pubmed: 34055030
PLoS One. 2022 Jan 21;17(1):e0262389
pubmed: 35061800
Clin Cancer Res. 2016 Oct 15;22(20):4968-4972
pubmed: 27407089
Am J Chin Med. 2014;42(3):543-59
pubmed: 24871650
Mol Cancer. 2007 Apr 02;6:24
pubmed: 17407548
Nucleic Acids Res. 2020 Jan 8;48(D1):D1031-D1041
pubmed: 31691823
Med Res Rev. 2014 Jul;34(4):768-94
pubmed: 24123144
Int J Cancer. 2020 Mar 15;146(6):1674-1685
pubmed: 31340060
Am J Chin Med. 2020;48(7):1577-1592
pubmed: 33202152
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W32-8
pubmed: 24792161
Cell Death Dis. 2015 Jul 30;6:e1834
pubmed: 26225773
Cancer Biomark. 2022;33(1):57-70
pubmed: 34366326
Phytother Res. 2018 Apr;32(4):667-671
pubmed: 29368408
Fish Shellfish Immunol. 2019 Oct;93:597-611
pubmed: 31400511
Mol Med Rep. 2012 Apr;5(4):1019-22
pubmed: 22246196
BMC Pharmacol Toxicol. 2020 May 1;21(1):32
pubmed: 32357920
Am J Surg. 2013 Nov;206(5):698-703
pubmed: 24011568
J Biol Chem. 2012 Dec 21;287(52):43234-45
pubmed: 23135268
Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368
pubmed: 27924014
Cancer Cell. 2019 Jan 14;35(1):64-80.e7
pubmed: 30612941
J Cheminform. 2014 Apr 16;6:13
pubmed: 24735618
Cancers (Basel). 2020 Apr 08;12(4):
pubmed: 32276534
Lancet. 2005 May 14-20;365(9472):1727-41
pubmed: 15894099
Biosci Rep. 2018 Nov 30;38(6):
pubmed: 30401729